Skip to main content

Table 3 Promoter hypermethylation of biomarkers in colorectal carcinomas (test and validation sets) compared with the patients clinico-pathological features and tumor phenotype

From: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

  CNRIP1 FBN1 INA MAL SNCA Panel
  M U M U M U M U M U Pos Neg
Tumors             
   No 169/179 10/179 142/179 37/179 117/179 62/179 162/179 17/179 119/179 60/179 168/179 11/179
Tumor phenotype             
   MSI 47 1 42 6 36 11 46 2 37 10 47 1
   MSS 122 9 100 31 81 51 116 15 82 50 121 10
   P value NS NS 7.4E-2 NS 7.6E-2 NS
BRAF ex15             
   Wild Type 136 10 109 37 87 59 129 17 89 57 135 11
   Mutation 33 0 33 0 30 3 33 0 30 3 33 0
   P value NS 2.5E-4 4.5E-4 3.9E-2 8.5E-4 NS
Sex             
   Male 83 6 71 18 57 32 81 8 57 32 81 8
   Female 86 4 71 19 60 30 81 9 62 28 87 3
   P value NS NS NS NS NS NS
Tumor site - 2 groups             
   Proximal 67 3 57 13 53 17 65 5 50 20 66 4
   Distal 100 7 83 24 63 44 95 12 67 40 100 7
   P value NS NS 2.4E-2 NS NS NS
Tumor site - 3 groups             
   Right 67 3 57 13 53 17 65 5 50 20 66 4
   Left 57 0 48 9 36 21 54 3 39 18 57 0
   Rectum 43 7 35 15 27 23 41 9 28 22 43 7
   P value 6.1E-3 NS 4.3E-2 5.5E-2 NS 1.1E-2
Stage             
   I 27 3 23 7 19 11 26 4 20 10 27 3
   II 76 3 60 19 54 25 72 7 52 27 75 4
   III 45 4 42 7 31 18 44 5 33 16 45 4
   IV 21 0 17 4 13 8 20 1 14 7 21 0
   P value NS NS NS NS NS NS
  1. Pearson's chi-square and Fisher's exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype have been published elsewhere [9].
  2. Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.